Erectile Dysfunction Drugs Market to reach around $ 2.63 Bn by 2025

May 31, 2019

Worldwide erectile dysfunction drugs market is presumed to accumulate about US $2.63 billion by the year 2025, according to the latest research available at Market Study Report LLC, report provides extensively data on market share, growth, trends and forecasts for the period 2017-2025.

Erectile dysfunction is a sexual dysfunctional condition, in which men are unable to maintain the erection during sexual intercourse. The World Health Organization claimed in a statement that sexual health is a vital aspect for the physical and emotional wellbeing of an individual, as well as for the social as well as economic development of countries & communities. Erectile dysfunction affects the quality of life adversely for both the partners and patients, and often results in relationship issues.

Commonly an age-related condition, erectile dysfunction can be stimulated by certain psychological factors. Several cardiovascular disorders including high blood pressure and clogged arteries, hormonal insufficiency, multiple sclerosis, diabetes, chronic kidney diseases, neurological problems, and penis, pelvis and bladder injuries, etc. are the leading causes of erectile dysfunction. Other key factors listed in the report include smoking, obesity, sedentary lifestyle, excessive intake of alcohol, and consumption of drugs like antidepressant, antihypertensive, recreational, and psychotropic drugs. However, exercise, well-maintained lifestyle, pharmacotherapy, penis implants, injections into penis and erection devices are recommended for the cure of erectile dysfunction. At present, oral phosphodiesterase type 5 inhibitors (PDE5I) is the frontline drug therapy for erectile dysfunction, prescribed by physicians. 

The adoption of erectile dysfunction drugs has bolstered significantly owing to the worldwide availability of oral drugs, surging awareness regarding erectile dysfunction and sexual diseases. The rising geriatric population, and the high rate of chronic diseases like diabetes, kidney failure, hormonal imbalance, hypertension, and neurological disorders, has further augmented the product demand. In addition, growing number of referrals to primary care and secondary care consultations is anticipated to boost the market growth during the forecast years.

Based on the drug type, the global erectile dysfunction market is segmented into Viagra (sildenafil citrate), Spedra/Stendra (avanafil), Staxyn/Levitra (vardenafil), Vitaros (alprostadil cream), Zydena (udenafil), and others. On the basis of component spectrum, the global market is fragmented into testosterone, PDE5I, alprostadil, and others. Medical experts claim that the lack of testosterone leads to impotence, and in such cases, testosterone hormones are prescribed to balance the hormone level in patient’s body. PDE5I is the most commonly advised drug for treating erectile dysfunction and, also thus holds a major market share in the global erectile dysfunction drugs market.

Request sample copy of this Report@

On the basis of dosage form, the global erectile dysfunction drugs market is fragmented into topical, oral, injections and others. Reportedly, the oral segment bagged a major market share in the global market. The report cites that the injections segment would expand at the highest CAGR throughout the estimated period. Speaking of the different distribution channel, the global market comprises hospital pharmacy, online pharmacy, and retail pharmacy.

Based on the geographical presence, the global erectile dysfunction drugs market is divided into five major regions, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The latest research report entails a comprehensive analysis of the global erectile dysfunction drugs market drivers, industry dynamics, and future trends, alongside a thorough scrutiny of market restraints & opportunities over the forecast period. The report also features an in-depth industry analysis which takes into consideration Porter’s five forces that include the degree of competition, bargaining power of supplier, bargaining power of buyer, the threat of new entrant, and the threat of substitute.

The well-known market players enumerated in the report include Bayer AG, Eli Lilly & Co., Pfizer, Vivus Inc., Dong-A Pharmaceutical Co. Ltd., S.K. Chemicals Co. Ltd., Apricus Biosciences, and Meda Pharmaceuticals, among others.